7 Oct/09
By Jim Mittler, PhD Creating a heightened focus on drug safety early in the drug development process is becoming the new paradigm for pharmaceutical companies. After hearing risk management...
2 Oct/09
By Jim Mittler, PhD Since 2007, the FDA has had the authority to require pharmaceutical companies to develop a risk evaluation and management strategy (REMS) for marketed products to ensure that...